ATOS Atossa Therapeutics Inc

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial results for the second quarter ended June 30, 2019 and provided an update on recent company developments.

Steven C. Quay, M.D., Ph.D., Atossa Genetics’ President and CEO commented, "During the quarter we were very pleased to have achieved our primary endpoint in our Phase 2 trial of topical Endoxifen to reduce mammographic breast density (MBD). We are now focusing our efforts on the oral formulation of Endoxifen and are developing a modified-release oral tablet which is being tested in a Phase 1 study and that we plan to use in a Phase 2 study to reduce MBD. The Phase 2 study is scheduled to start in the fourth quarter and should be completed by mid-2020. We completed the quarter with $17.1 million in cash, which will enable us to continue to make clinical progress with our programs."

Recent Developments 

Recent developments include the following:

• July 2019 – Provided update on expanded access program, which now allows physicians and patients to visit the company website to obtain information on compassionate use access
• July 2019 – Initiated a Phase 1 study of our proprietary modified-release oral Endoxifen tablet
• June 2019 – Successfully reached the primary endpoint of MBD reduction using the topical formulation of Endoxifen in a Phase 2 study

Q2 2019 Financial Results 

For the three and six months ended June 30, 2019 and 2018, we have no source of sustainable revenue and no associated cost of revenue.

Total operating expenses were approximately $7,286,000 and $11,350,000 for the three and six months ended June 30, 2019, respectively, consisting of research and development (R&D) expenses of approximately $2,612,000 and $4,063,000 respectively, and general and administrative (G&A) expense of approximately $4,674,000 and $7,287,000, respectively. Total operating expenses were approximately $4,143,000 and $6,017,000 for the three and six months ended June 30, 2018, respectively, consisting of research and development expenses of approximately $1,468,000 and $1,939,000, respectively, and general and administrative expenses of approximately $2,675,000 and $4,078,000, respectively.

R&D expenses for the three months ended June 30, 2019, were approximately $2,612,000, an increase of approximately $1,144,000 or 78% from total R&D expenses for the three months ended June 30, 2018 of approximately $1,468,000. R&D expenses for the six months ended June 30, 2019, were approximately $4,063,000, an increase of approximately $2,124,000 or 110% from total R&D expenses for the six months ended June 30, 2018 of approximately $1,939,000.  The increase in R&D expenses for the period ended June 30, 2019, is mainly attributed to an increase in stock-based compensation expense (non-cash). We expect our R&D expenses to increase throughout 2019 as we commence an additional Phase 2 clinical study of oral Endoxifen, develop and manufacture our modified release tablet form of oral Endoxifen, continue our clinical trial of Fulvestrant administered via our intraductal technology and continue the development of other indications and therapeutics, including CAR-T and immunotherapies administered via our intraductal technologies.

G&A expenses were approximately $4,674,000 for the three months ended June 30, 2019, an increase of approximately $1,999,000, or 75% from the total G&A expenses for the three months ended June 30, 2018, of approximately $2,675,000. G&A expenses were approximately $7,287,000 for the six months ended June 30, 2019, an increase of approximately $3,209,000, or 79% from the total G&A expenses for the six months ended June 30, 2018, of approximately $4,078,000. G&A expenses consist primarily of personnel and related benefit costs, facilities, professional services, insurance, and public company related expenses. The increase in G&A expenses for the period ended June 30, 2019, is mainly attributed to an increase in stock-based compensation expense (non-cash). Additionally, payroll expenses have increased resulting from salary increases over the prior year.

As of June 30, 2019, Atossa had approximately $17.1 million in cash and cash equivalents and working capital of approximately $17.4 million.

About Atossa Genetics 

Atossa Genetics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa's drugs under development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Genetics Company Contact: Atossa Genetics Inc. Kyle Guse CFO and General Counsel Office: 866 893-4927 kyle.guse@atossagenetics.com

Investor Relations Contact: Scott Gordon Core IR377 Oak StreetConcourse 2Garden City, NY 11530Office:(516) 222-2560scottg@corprominence.com 

Source: Atossa Genetics Inc.

ATOSSA GENETICS INC.CONDENSED CONSOLIDATED BALANCE SHEETS

		As of June 30,					As of
		2019				December 31,
Assets		(Unaudited)				2018
Current assets
Cash and cash equivalents		$	17,058,527			$	10,380,493
Restricted cash			110,000				110,000
Prepaid expenses			813,168				509,833
Research and development tax rebate receivable			406,306				518,098
Other current assets			140				30,942
Total current assets			18,388,141				11,549,366
Furniture and equipment, net			44,174				54,487
Intangible assets, net			83,958				99,375
Right-of-use asset			75,822				-
Other assets			17,218				17,218
Total Assets		$	18,609,313			$	11,720,446
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable		$	318,266			$	353,328
Accrued expenses			53,485				177,074
Payroll liabilities			589,445				935,070
Stock-based compensation liability			-				1,410,025
Lease liability			51,795				-
Other current liabilities			19,838				39,939
Total current liabilities			1,032,829				2,915,436
Long term liabilities
Lease liability long term			24,027				-
Total Liabilities			1,056,856				2,915,436
Commitments and contingencies
Stockholders' equity
Preferred stock - $0.001 par value; 10,000,000 shares authorized; 676 and 2,379shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively			1				2
Additional paid-in capital- Series B convertible preferred stock			675,999				2,378,997
Common stock - $0.18 par value; 175,000,000 shares authorized, and 9,129,563 and5,846,552 shares issued and outstanding, as of June 30, 2019 and December 31, 2018, respectively			1,643,309				1,052,372
Additional paid-in capital			103,400,247				82,204,902
Accumulated deficit			(88,167,099	)			(76,831,263	)
Total Stockholders' Equity			17,552,457				8,805,010
Total Liabilities and Stockholders' Equity		$	18,609,313			$	11,720,446

ATOSSA GENETICS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)

		For the Three MonthsEnded June 30,										For the Six MonthsEnded June 30,
						2018											2018
		2019				(as restated)							2019				(as restated)
Operating expenses
Research and development		$	2,611,948			$	1,467,736						$	4,063,184			$	1,938,712
General and administrative			4,674,121				2,674,920							7,287,214				4,078,385
Total operating expenses			7,286,069				4,142,656							11,350,398				6,017,097
Operating loss			(7,286,069	)			(4,142,656		)					(11,350,398	)			(6,017,097		)
Other income			23,540				79							14,562				138
Loss before income taxes			(7,262,529	)			(4,142,577		)					(11,335,836	)			(6,016,959		)
Income taxes			-				-							-				-
Net loss		$	(7,262,529	)		$	(4,142,577		)				$	(11,335,836	)		$	(6,016,959		)
Deemed dividends attributable to preferred stock			-				(11,479,308		)					-				(11,479,308		)
Net loss applicable to common shareholders		$	(7,262,529	)		$	(15,621,885		)				$	(11,335,836	)		$	(17,496,267		)
Loss per common share - basic and diluted		$	(0.80	)		$	(5.08		)				$	(1.44	)		$	(6.11		)
Weighted average shares outstanding - basic and diluted			9,126,153				3,073,803							7,852,907				2,864,033